Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Fosun Pharma (PFE) subsidiary Yao Pharma and Pfizer (PFE) entered an exclusive global collaboration and license agreement on December 9, 2025.

Rhea-AI Summary

Fosun Pharma (PFE) subsidiary Yao Pharma and Pfizer (PFE) entered an exclusive global collaboration and license agreement on December 9, 2025.

Yao Pharma will complete a Phase 1 trial of oral small‑molecule GLP‑1R agonist YP05002 in Australia and grants Pfizer an exclusive worldwide license to develop, manufacture and commercialize YP05002 and related oral small‑molecule GLP‑1R agonists for all human and veterinary indications.

Financial terms include an upfront payment of $150 million, up to $1.935 billion in development/regulatory/commercial milestone payments, plus tiered royalties on sales.

Positive

• $150M upfront payment to Yao Pharma
• Up to $1.935B in potential milestone payments
• Exclusive worldwide license covering development, manufacturing, commercialization
• Yao Pharma to complete Phase 1 trial of YP05002 in Australia

Negative

• None.

Argus Dec 9 session

-1.71% close to close Open Argus

Details

News Market Reaction – PFE

On Dec 9, the day this news came out, PFE closed 1.71% below the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Key Figures

Upfront payment: $150 million Milestone potential: $1.935 billion

Upfront payment

$150 million

Paid by Pfizer to Yao Pharma under the GLP-1 collaboration

Milestone potential

$1.935 billion

Maximum development, regulatory and commercial milestones payable to Yao Pharma

Historical Context

5 past events · Latest: Dec 01

5 events

1. Dec 01

   Guidance conference call

   24h Move

   -1.8%

   Announcement of upcoming call to provide full-year 2026 financial guidance.

2. Nov 21

   FDA approval

   24h Move

   +2.6%

   FDA approval of PADCEV plus Keytruda for muscle-invasive bladder cancer patients.

3. Nov 13

   Strategic acquisition

   24h Move

   -0.3%

   Completion of Metsera acquisition adding late-stage and Phase 1 GLP-1 and hormone assets.

4. Nov 12

   Investor conference

   24h Move

   +1.4%

   Webcast announcement for CFO discussion at a healthcare investor conference.

5. Nov 04

   Earnings and guidance

   24h Move

   -1.5%

   Q3 2025 results with $16.7B revenue and raised 2025 EPS guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glucagon-like peptide-1 receptor (GLP-1R) agonists, phase 1 clinical trial, metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic steatohepatitis (NASH)

4 terms

glucagon-like peptide-1 receptor (GLP-1R) agonists medical

"oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002"

Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of medicines that activate a specific hormone receptor involved in blood sugar control and appetite regulation; think of them as a key that fits a receptor “lock” to turn on signals that lower glucose and reduce hunger. They matter to investors because they treat common chronic conditions like type 2 diabetes and obesity, creating large markets where regulatory approvals, clinical trial results, pricing, and manufacturing capacity can quickly change a company’s revenue outlook.

phase 1 clinical trial medical

"Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

metabolic dysfunction-associated steatohepatitis (MASH) medical

"potential indications including but not limited to ... metabolic dysfunction-associated steatohepatitis (MASH)"

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.

non-alcoholic steatohepatitis (NASH) medical

"metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH)"

Non-alcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and fat buildup in the liver not caused by alcohol consumption. It can lead to serious health problems like liver scarring or failure if left untreated. For investors, NASH is significant because it represents a growing area of medical need, driving demand for new treatments and innovation in healthcare markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide. Yao Pharma will receive an upfront payment of $150 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion, as well as tiered royalties on sales, if approved.

The licensed small-molecule GLP-1R agonists were independently researched and developed by Fosun Pharma's subsidiary Yao Pharma with proprietary intellectual property rights and are intended for the treatment of metabolic diseases, with potential indications including but not limited to chronic weight management, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), among others. YP05002 is currently in Phase 1 clinical development in Australia.

"The partnership with Pfizer marks the international recognition of Yao pharma's R&D capabilities. We firmly believe that only through openness and collaboration can the value of innovation be maximized." Mr. Liu Qiang, Chairman of Yao Pharma, stated, "Leveraging Pfizer's exceptional global development experience and commercialization network, along with Yao Pharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to enable this innovative drug candidate to be developed and commercialized in order to benefit patients worldwide more quickly and broadly."

"The global collaboration with Pfizer is another significant milestone in Fosun Pharma's strategy of innovation and internationalization." Mr. Chen Yuqing, Chairman of Fosun Pharma, said, "Fosun Pharma is committed to addressing unmet clinical needs. We look forward to working with Pfizer to expedite the global development and commercialization of YP05002, with the goal of working toward addressing the challenges of obesity and metabolic diseases for patients in need."

View original content:https://www.prnewswire.com/news-releases/fosun-pharmas-subsidiary-yao-pharma-and-pfizer-enter-into-exclusive-collaboration-and-license-agreement-302636496.html

SOURCE Fosun Pharma

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Yao Pharma and Pfizer announce on December 9, 2025 regarding YP05002 (PFE)?

They announced an exclusive worldwide collaboration and license granting Pfizer rights to develop, manufacture, and commercialize oral GLP‑1R candidate YP05002.

How much did Pfizer pay upfront to Yao Pharma in the December 9, 2025 deal (PFE)?

Pfizer will pay Yao Pharma an upfront amount of $150 million.

What is the maximum milestone potential in the Pfizer–Yao Pharma agreement announced December 9, 2025 (PFE)?

Yao Pharma is eligible to receive up to $1.935 billion in development, regulatory, and commercial milestone payments.

Which indications are targeted by the licensed oral GLP‑1R agonists in the Pfizer deal (PFE)?

The license covers metabolic disease indications including chronic weight management, type 2 diabetes, and MASH/NASH, among others.

What development step will Yao Pharma complete before Pfizer takes over global development (PFE)?

Yao Pharma will complete the ongoing Phase 1 clinical trial of YP05002 in Australia.

Will Pfizer have exclusive global rights to manufacture and commercialize YP05002 after the December 9, 2025 agreement (PFE)?

Yes; the agreement grants Pfizer an exclusive worldwide license to develop, manufacture, and commercialize YP05002 and related oral small‑molecule GLP‑1R agonists.